Human Growth Hormone

  • Salvatore Raiti
  • Robert A. Tolman

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Introduction I

    1. Salvatore Raiti
      Pages 1-11
  3. Introduction II

    1. Robert A. Tolman
      Pages 13-18
  4. Hypopituitarism and Hyperpituitarism

    1. Front Matter
      Pages 19-19
    2. Henry G. Friesen, Heather J. Dean, Susan Kasper
      Pages 21-28
    3. Mark E. Molitch
      Pages 29-50
    4. Salvatore Raiti, S. L. Kaplan, W. V. Moore, J. S. Parks, M. H. MacGillivray, A. W. Root et al.
      Pages 77-83
    5. Wayne V. Moore, Libbie J. Russo
      Pages 85-91
    6. Robert M. Blizzard, Susan Joyce, Tina Mitchell, Ann J. Johanson, Samuel Libber, Leslie P. Plotnick et al.
      Pages 93-106
  5. Human Growth Hormone in other Forms of Short Stature

    1. Front Matter
      Pages 107-107
    2. Salvatore Raiti, S. L. Kaplan, G. P. August, S. A. Kaplan, M. H. MacGillivray, W. V. Moore et al.
      Pages 109-113
    3. G. Van Vliet, D. M. Styne, S. L. Kaplan, M. M. Grumbach
      Pages 115-121
    4. Salvatore Raiti, S. L. Kaplan, G. P. August, S. A. Kaplan, M. H. MacGillivray, W. V. Moore et al.
      Pages 123-126
    5. Daniel Rudman, Rajender K. Chawla, William P. Heath, Carol J. Berry, Michael H. Kutner
      Pages 135-162
    6. Zvi Laron, Aviva Silbergeld, Athalia Pertzelan, Rina Eshet
      Pages 163-178

About this book

Introduction

It has been ten years since the National Hormone and Pituitary Program (then called the National Pituitary Agency) sponsored a symposium on human growth hormone (hGH). Numerous advances have occurred during this period. This book does not attempt to summarize past achievements. Rather, it deals with the contemporary issues in hGH research. A discussion of the present state of the art, of necessity, includes a review of the past. Some of the topics herein discussed include the following: 1. Growth hormone releasing factor (GRF). In 1973, the growth hormone inhibitory factor (somatostatin) had recently been discovered. The search for a releasing factor in humans led to its discovery not in the pituitary but in a pancreatic tumor that secreted growth hormone. The advances are discussed in this book. The current hope is that GRF will eventually become an effective therapeutic agent for idiopathic hypopituitarism in childhood and adolescence. 2. Biosynthesis of hGR by recombinant DNA technology. Current advances are discussed. Although hGH is not yet an approved drug, it will eventually become one. This will broaden our horizons in terms of hGH effectiveness in disorders other than hypopituitary dwarfism. The current experience with this type of hGH in both the Vnited States and Europe is reviewed by several authors.

Keywords

DNA G proteins biosynthesis childhood drug growth growth factor growth hormone hormone hormone therapy insulin physiology research tumor

Editors and affiliations

  • Salvatore Raiti
    • 1
  • Robert A. Tolman
    • 2
  1. 1.National Hormone and Pituitary ProgramBaltimoreUSA
  2. 2.National Institute of Arthritis, Diabetes and Digestive and Kidney DiseasesBethesdaUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4615-7201-5
  • Copyright Information Springer-Verlag US 1986
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4615-7203-9
  • Online ISBN 978-1-4615-7201-5
  • About this book